Andrew A Kanner

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/12170371/publications.pdf

Version: 2024-02-01

34 papers

2,586 citations

16 h-index 454577 30 g-index

34 all docs

34 docs citations

times ranked

34

3302 citing authors

#	Article	IF	CITATIONS
1	Maintenance Therapy With Tumor-Treating Fields Plus Temozolomide vs Temozolomide Alone for Glioblastoma. JAMA - Journal of the American Medical Association, 2015, 314, 2535.	3.8	982
2	NovoTTF-100A versus physician's choice chemotherapy in recurrent glioblastoma: A randomised phase III trial of a novel treatment modality. European Journal of Cancer, 2012, 48, 2192-2202.	1.3	661
3	RTOG 0631 phase 2/3 study of image guided stereotactic radiosurgery for localized (1-3) spine metastases: Phase 2 results. Practical Radiation Oncology, 2014, 4, 76-81.	1.1	205
4	Influence of Treatment With Tumor-Treating Fields on Health-Related Quality of Life of Patients With Newly Diagnosed Glioblastoma. JAMA Oncology, 2018, 4, 495.	3.4	135
5	Post Hoc Analyses of Intention-to-Treat Population in Phase III Comparison of NovoTTF-100Aâ,,¢ System Versus Best Physician's Choice Chemotherapy. Seminars in Oncology, 2014, 41, S25-S34.	0.8	80
6	Intracranial navigation by using low-field intraoperative magnetic resonance imaging: preliminary experience. Journal of Neurosurgery, 2002, 97, 1115-1124.	0.9	62
7	Posterior Fossa Metastases: Risk of Leptomeningeal Disease When Treated with Stereotactic Radiosurgery Compared to Surgery. Journal of Neuro-Oncology, 2004, 67, 115-121.	1.4	60
8	Radiosurgical treatment planning of AVM following embolization with Onyx: possible dosage error in treatment planning can be averted. Journal of Neuro-Oncology, 2010, 98, 271-276.	1.4	51
9	Health-related quality of life, cognitive screening, and functional status in a randomized phase III trial (EF-14) of tumor treating fields with temozolomide compared to temozolomide alone in newly diagnosed glioblastoma. Journal of Neuro-Oncology, 2017, 135, 545-552.	1.4	48
10	The impact of genotype on outcome in oligodendroglioma: validation of the loss of chromosome arm 1p as an important factor in clinical decision making. Journal of Neurosurgery, 2006, 104, 542-550.	0.9	43
11	Posterior Fossa Metastases: Aggressive Treatment Improves Survival. Stereotactic and Functional Neurosurgery, 2003, 81, 18-23.	0.8	32
12	Cyclooxygenase-2 in oligodendroglial neoplasms. Cancer, 2003, 98, 1465-1472.	2.0	29
13	Stereotactic radiosurgery (SRS) in high-grade glioma: judicious selection of small target volumes improves results. Journal of Neuro-Oncology, 2016, 126, 551-557.	1.4	24
14	Regression of intracranial meningioma following treatment with nivolumab: Case report and review of the literature. Journal of Clinical Neuroscience, 2017, 37, 51-53.	0.8	23
15	Patterns of Failure after Stereotactic Radiosurgery of the Resection Cavity FollowingÂSurgical Removal of Brain Metastases. World Neurosurgery, 2015, 84, 1825-1831.	0.7	20
16	Radiotherapy of nonfunctioning and gonadotroph adenomas. Pituitary, 2009, 12, 15-22.	1.6	19
17	Craniectomy Versus Craniotomy for Posterior Fossa Metastases: Complication Profile. World Neurosurgery, 2016, 89, 193-198.	0.7	18
18	Surgical Therapies in Brain Metastasis. Seminars in Oncology, 2007, 34, 197-205.	0.8	16

#	Article	IF	CITATIONS
19	Surgery for Recurrent High-Grade Glioma After Treatment with Bevacizumab. World Neurosurgery, 2018, 110, e727-e737.	0.7	14
20	Combined treatment approach to cerebral arteriovenous malformation in pediatric patients: stereotactic radiosurgery to partially Onyx-embolized AVM. Child's Nervous System, 2018, 34, 2269-2274.	0.6	13
21	Detection of gene mutations and gene–gene fusions in circulating cellâ€free DNA of glioblastoma patients: an avenue for clinically relevant diagnostic analysis. Molecular Oncology, 2022, 16, 2098-2114.	2.1	13
22	Impact of Onyx Embolization on Radiosurgical Management of Cerebral Arteriovenous Malformations: Treatment and Outcome. World Neurosurgery, 2017, 108, 656-661.	0.7	9
23	Height as a risk factor in meningioma: a study of 2 million Israeli adolescents. BMC Cancer, 2020, 20, 786.	1.1	7
24	Neurocognitive evaluation of brain metastases patients treated with post-resection stereotactic radiosurgery: a prospective single arm clinical trial. Journal of Neuro-Oncology, 2018, 140, 307-315.	1.4	6
25	Height in adolescence as a risk factor for glioma subtypes: a nationwide retrospective cohort study of 2.2 million subjects. Neuro-Oncology, 2021, 23, 1383-1392.	0.6	5
26	TAMI-40. TUMOR MICROBIOME AND GLIOBLASTOMA (GBM). Neuro-Oncology, 2020, 22, ii221-ii222.	0.6	4
27	Should the subventricular zone be part of the "rad―zone?. Journal of Neuro-Oncology, 2014, 118, 423-424.	1.4	3
28	Corrigendum to "Post Hoc Analyses of Intention-to-Treat Population in Phase III Comparison of NovoTTF-100Aâ,,¢ System Versus Best Physician's Choice Chemotherapy'' [Seminars in Oncology, Vol No 5,Suppl 6, October 2014, pp S25-S34]. Seminars in Oncology, 2015, 42, e56-e66.	\$ 1\$	1
29	Supportive Care in Patients Using Tumor Treating Fields Therapy. , 2016, , 103-116.		1
30	Multicentric non-enhancing lesions in glioblastoma: A retrospective study. Journal of Clinical Neuroscience, 2021, 85, 20-26.	0.8	1
31	Synergy-S stereotactic radiosurgery for spinal tumors. Israel Medical Association Journal, 2013, 15, 678-81.	0.1	1
32	SURG-26COMPLICATION PROFILE: COMPARING CRANIECTOMY AND CRANIOTOMY FOR POSTERIOR FOSSA METASTASES. Neuro-Oncology, 2015, 17, v220.1-v220.	0.6	0
33	Future Directions for Tumor Treating Fields. , 2016, , 117-126.		0
34	PATH-24. DETECTION OF POINT MUTATIONS AND GENE FUSIONS FROM CIRCULATING CELL-FREE DNA (CFDNA) OF GLIOBLASTOMA (GBM) PATIENTS. Neuro-Oncology, 2020, 22, ii169-ii169.	0.6	0